IMNM 10.52 ▲ 7.35% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Immunome Inc.

    NASDAQ: IMNM · Real-Time Price · USD
    10.52
    0.72 (7.35%)
    At close: Sep 05, 2025, 3:59 PM
    10.58
    0.57%
    After-hours: Sep 05, 2025, 07:42 PM EDT
    7.35%
    Bid 9.81
    Market Cap 915.71M
    Revenue (ttm) 12.59M
    Net Income (ttm) -212.39M
    EPS (ttm) -3.05
    PE Ratio (ttm) -3.45
    Forward PE -4.21
    Analyst Buy
    Ask 10.74
    Volume 1,347,065
    Avg. Volume (20D) 870,577
    Open 10.16
    Previous Close 9.80
    Day's Range 10.06 - 10.65
    52-Week Range 5.15 - 16.73
    Beta 1.92

    About IMNM

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol IMNM
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for IMNM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Immunome Inc. is scheduled to release its earnings on Nov 12, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    5 months ago
    +7.19%
    Immunome shares are trading higher after Lake Stre... Unlock content with Pro Subscription
    7 months ago
    +1.19%
    Immunome shares are trading lower after the company announced a $125 million proposed public offering.
    news image

    1 day ago · businesswire.com

    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...

    news image

    3 weeks ago · seekingalpha.com

    Immunome: SpringWorks Buyout Informs The Potential Upside Here

    Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 topline data expected by the end of 2025. IMNM holds Orphan Drug designations in the US and Europe, potent...

    news image

    1 month ago · zacks.com

    Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates

    Immunome, Inc. (IMNM) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.49 per share a year ago.

    news image

    1 month ago · fool.com

    Immunome (IMNM) Q2 Revenue Surges 382%

    Immunome (IMNM -3.59%), a clinical-stage biotechnology company developing targeted therapies for cancer, reported its second quarter 2025 earnings on August 6, 2025. The standout news was a substantia...

    news image

    2 months ago · zacks.com

    Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?

    Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d...

    news image

    2 months ago · zacks.com

    Immunome (IMNM) Upgraded to Buy: Here's What You Should Know

    Immunome (IMNM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    2 months ago · zacks.com

    Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?

    The average of price targets set by Wall Street analysts indicates a potential upside of 158.2% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the posi...

    Add to Watchlist